StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

LENZ Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 97.8%.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202597.8%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202694.9%–
Q1 FY2026Mar 31, 202643.4%–
Q2 FY2025Jun 30, 2025100.0%–

More LENZ Therapeutics figures

See a number that looks wrong?